Abstract
Aim:
To examine the antihypertrophic effect of ginsenoside Rb1 (Rb1) induced by prostaglandin F2α(PGF2α) in vitro and to investigate the possible mechanisms involved in the calcineurin (CaN) signal transduction pathway.
Methods:
The cardiomyocyte hypertrophy induced by PGF2α and the antihypertrophic effect of Rb1 were evaluated in primary culture by measuring the cell diameter, protein content, and atrial natriuretic peptide (ANP) mRNA expression. ANP and CaN mRNA expressions, CaN and its downstream effectors NFAT3 and GATA4 protein expressions, and the intracellular free Ca2+ concentration ([Ca2+]i) were assayed by RT-PCR, Western blot, and fluorescent determination using Fura 2/AM, respectively.
Results:
PGF2α(100 nmol/L) significantly increased the cardiomyocyte diameter, protein content and [Ca2+]i, and promoted ANP, CaN mRNA, and CaN/NFAT3/GATA4 protein expressions, which were inhibited by either Rb1 in a concentration-dependent manner (50,100, and 200 μg/mL) or L-arginine (1 mmol/L). NG-nitro-L-arginine-methyl ester, a nitric oxide synthase inhibitor, could abolish the effects of L-arginine, but failed to change the effects of Rb1 in the experiments above.
Conclusion:
The present data implicate that Rb1 attenuates cardiac hypertrophy, the underlying mechanism may be involved in the inhibition of the Ca2+-CaN signal transduction pathway.
Similar content being viewed by others
Article PDF
References
Hunter JJ, Chien KR . Signaling pathways for cardiac hypertrophy and failure. N Engl Med 1999; 341: 1276–83.
Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevents cardiac dysfunction despite increased wall stress. Circulation 2002; 105: 85–92.
Jacobs TF, Ramsey LA . Angiotensin receptor blockers. Applications beyond hypertension. Adv Nurse Pract 2005; 13: 27–30.
Zhang R, Crump J, Reisin E . Regression of left ventricular hypertrophy is a key goal of hypertension management. Curr Hypertens Rep 2003; 5: 301–8.
Messerli FH . Evolution of calcium antagonists: past, present, and future. Clin Cardiol 2003; 26 ( Suppl 2): II12–6.
Kempf T, Wollert KC . Nitric oxide and the enigma of cardiac hypertrophy. Bioassays 2004; 26: 608–15.
Zhang JL, Xu WA, Yang YK, Zhang EY, Wang ZY, Zhang YZ . A primarily study on the relationship between the effect of Panax Notoginsen Rb1 Rg1 on the aging process. Acad J Kunming Med 2000; 21: 63–5. Chinese.
Jiang S, Jiang ZL . Protective effect of ginsenoside Rb1 on ischemic brain injury in rat. J Apoplexy Nervous Diseases 2003; 20: 415–7.
Guan L, Li W, Liu Z . Effect of ginsenoside Rb1 on cardiomyocyte apoptosis after ischemia and reperfusion in rats. J Huazhong Univ Sci Technol Med Sci 2002; 22: 212–5. Chinese.
Scott GI, Colligan PB, Ren BH, Ren J . Ginsenosides Rb1 and Re decrease cardiac contraction in adult rat ventricular myocytes: role of nitric oxide. Br J Pharmacol 2001; 134: 1159–65.
Jiang XY, Zhang JT, Shi CZ . Mechanism of action of ginsenoside Rb1 in decreasing intracellular Ca2+. Yao Xue Xue Bao 1996; 31: 321–6. Chinese.
Liu M, Zhang JT . Effects of ginsenoside Rb1 and Rg1 on synaptosomal free calcium level, ATPase and calmodulin in rat hippocampus. Chin Med J 1995; 108: 544–7.
Zhang WJ, Zhong GG, Jiang Y, Wang XM, Wang ZF . Single channel analysis on calcium channel blocked action of panaxadiol and panaxatriol saponins on cultured rat ventricular myocytes. Acta Pharmacol Sin 1994; 15: 173–6. Chinese.
Lai J, Jin H, Yang R, Winer J, Li W, Yen R, et al. Prostaglandin F2 alpha induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. Am J Physiol 1996; 271: H2197–208.
Sugden PH . Signaling pathways in cardiac myocyte hypertrophy. Ann Med 2001; 33: 611–22.
Zhang W . Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy. Cardiovasc Res 2002; 53: 294–303.
De Windt LJ, Lim HW, Haq S, Force T, Molkentin JD . Calcineurin promotes protein kinase C and c-jun NH2-terminal kinase activation in the heart, cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem 2000; 275: 13571–9.
Hogan PG, Chen L, Nardone J, Rao H . Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003; 17: 2205–32.
Vega RB, Bassel-Duby R, Olson EN . Control of cardiac growth and function by calcineurin signaling. J Biol Chem 2003; 278: 36981–4.
Xu SY, editor. Methodologies of pharmacological experiment. Beijing: The People's Medical Publishing House; 2002.
Lei KJ, Huang XN, Wu Q, Xie XL, Yu LM, Lu YF . The effects of breviscapine on platelet aggregation and intra-platelet free calcium. Acta Acad Med Zunyi 2004; 27: 11–3. Chinese.
Taigen T, De Windt LJ, Molkentin JD . Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 2000; 97: 1196–201.
Abassi Z, Brodsky S, Gealekman O, Rubinstein I, Hoffman A, Winaver J . Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure. Am J Physiol Renal Physiol 2001; 280: F43–53.
Ng DC, Long CS, Bogoyevitch MA . A role for the extracellular signal regulated kinase and p38 mitogen-activated protein ki-nases in interleukin-1 beta-stimulated delayed signal transducer and activator of transcription 3 activation, atrial natriuretic factor expression, and cardiac myocyte morphology. J Biol Chem 2001; 276: 29490–8.
Nakagami H, Takemoto M, Liao JK . NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 2003; 35: 851–9.
Fujino H, Srinivasan D, Pierce KL, Regan JW . Differential regulation of prostaglandin F2α receptor isoforms by protein kinase C. Mol Pharmacol 2000; 57: 353–8.
Chi en KR, Grace AA, Hunter JJ . Molecular and cellular biology of cardiac hypertrophy and failure. In: Chien KR, editor. Molecular basis of cardiovascular disease. Beijing: People's Medical Publishing House; 2001. p 211–50.
Molkentin JD . Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res 2000; 87: 731–8.
Jiang QS, Huang XN, Yang GZ, Dai ZK, Zhou QX, Shi JS, et al. Signal transduction pathway of cardiac hypertrophy induced by prostaglandin F2α may be mediated by calcineurin in rats. Acta Physiol Sin 2005; 57: 742–8.
Fiedler B, Wollert KC . Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes. Cardiovasc Res 2004; 63: 450–7.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the Science Foundation of Guizhou Province, China (No 2004-3057).
Rights and permissions
About this article
Cite this article
Jiang, Qs., Huang, Xn., Yang, Gz. et al. Inhibitory effect of ginsenoside Rb1 on calcineurin signal pathway in cardiomyocyte hypertrophy induced by prostaglandin F2α. Acta Pharmacol Sin 28, 1149–1154 (2007). https://doi.org/10.1111/j.1745-7254.2007.00601.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00601.x
Keywords
This article is cited by
-
Role of Chinese Herbal Medicines in Regulation of Energy Metabolism in Treating Cardiovascular Diseases
Chinese Journal of Integrative Medicine (2019)
-
Ginsenoside Rb1 Ameliorates Autophagy of Hypoxia Cardiomyocytes from Neonatal Rats via AMP-Activated Protein Kinase Pathway
Chinese Journal of Integrative Medicine (2019)
-
Barbaloin inhibits ventricular arrhythmias in rabbits by modulating voltage-gated ion channels
Acta Pharmacologica Sinica (2018)
-
Evodiamine Inhibits Angiotensin II-Induced Rat Cardiomyocyte Hypertrophy
Chinese Journal of Integrative Medicine (2018)
-
Cardioprotection of ginsenoside Rb1 against ischemia/reperfusion injury is associated with mitochondrial permeability transition pore opening inhibition
Chinese Journal of Integrative Medicine (2016)